Recombinant Human IGF-BP7

Lyophilized protein is stable for 2 years at -20C. Reconstituted protein is stable for 1 week at 2-4C or for 3 months in working aliquots with a carrier protein (0.1% HSA or BSA) at -20C. Please note that the addition of any carrier protein into this product may produce unwanted endotoxin. This depends upon the particular application employed. Avoid repeated freeze-thaw cycles.

IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP7 is expressed in a wide range of normal human tissues and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin. It plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF induced differentiation of skeletal myoblasts, without affecting IGF induced proliferation. Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF independent mechanism, which causes a delay in the G1 phase of the cell cycle, and increased apoptosis. Recombinant human IGF-BP7 is a 26.4 kDa protein consisting of 257 amino acid residues.

Centrifuge vial prior to opening. The human IGF-BP7 should be reconstituted in water to a concentration of 0.1-1.0 mg/ml. This solution can be diluted into other aqueous buffers and stored at 4C for 1 week or at -20C for future use.